Search results for "T lymphocyte"

showing 8 items of 208 documents

Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets

2021

Diabetic foot ulcer (DFU) is a well-known complication of diabetes and a significant burden on the national health systems. The neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio are inexpensive and easily accessible biomarkers that have proved to be useful in several inflammatory, infectious and cardiovascular diseases. We carried out a comprehensive review examining the association of NLR and PLR with the onset and progression of DFU. PLR and NLR were significantly increased in patients with DFU, compared with a control group of T2DM patients without DFU, and correlate well with DFU severity, evaluated by Wagner and IWGDF grading scales. In patients with diabetic foot infect…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentOsteomyelitisGeneral MedicineSystemic inflammationmedicine.diseaseGastroenterologyDiabetic foot ulcerAmputationDiabetes mellitusInternal medicinediabetes diabetic foot ulcer inflammation neutrophil-to-lymphocyte ratio (NLR) platelet lymphocyte ratio (PLR)medicineSurgeryClinical significancemedicine.symptomNeutrophil to lymphocyte ratioComplicationbusiness
researchProduct

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

2002

Mutations and aberrant expression of the p53 tumor suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the wild-type (wt) p53 protein and presented by major histocompatibility complex (MHC) molecules for T lymphocyte recognition are believed to serve as universal tumor-associated antigens for cancer immunotherapy. We studied the immunogeneicity of a recombinant replication-defective adenoviral vector encoding human full-length wt p53 (rAd/hup53) in human leukocyte antigen (HLA)-A2K(b)-transgenic (Tg) mice and man. The generation of p53 epitope-specific cytotoxic T lymphocytes (CTLs) in p53-proficient and p53-deficient A2K(b)-Tg mice was …

medicine.medical_treatmentGenetic VectorsEpitopes T-LymphocyteMice TransgenicPilot ProjectsHuman leukocyte antigenBiologyMajor histocompatibility complexCancer VaccinesEpitopeAdenoviridaeMiceImmune systemCancer immunotherapyAntigenSpecies SpecificityNeoplasmsHLA-A2 AntigenGeneticsmedicineCytotoxic T cellAnimalsHumansTreatment FailureMolecular BiologyT lymphocyteGenetic TherapyGenes p53Self ToleranceImmunologybiology.proteinMolecular MedicineTumor Suppressor Protein p53T-Lymphocytes CytotoxicGene therapy
researchProduct

HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides

2003

SUMMARY Ankylosing spondylitis (AS) is an inflammatory systemic disease affecting the spine, sacroiliacal and peripheral joints. Although the aetiology of AS remains unknown, the strong association with the HLA-B27 allele might reflect directly a detrimental effect of the HLA-B27 molecule itself, resulting from its potential capability to present ‘arthritogenic’ peptides to CD8+ T cells. Because some forms of SpA are triggered by enterobacterial infection, such arthritogenic peptides might originate from autologous and/or bacterial proteins triggering cross-reactive CD8+ T cell clones. Intriguingly, two peptides from the second extracellular domain of HLA-B*2705 share sequence homologies wi…

musculoskeletal diseasesAdultCytotoxicity ImmunologicMaleT cellReceptors Antigen T-Cell alpha-betaImmunologyComplementarity determining regionCD8-Positive T-LymphocytesAutoantigensEpitopeCell LineEpitopesAntigenClinical StudiesImmunology and AllergyMedicineHumansSpondylitis AnkylosingCells CulturedHLA-B27 AntigenAgedAged 80 and overHLA-B27Antigens Bacterialbusiness.industryTumor Necrosis Factor-alphaELISPOTT lymphocyteMiddle AgedComplementarity Determining Regionsmedicine.anatomical_structureImmunologyFemalebusinessPeptidesCD8
researchProduct

Identification of the Yersinia enterocolitica urease beta subunit as a target antigen for human synovial T lymphocytes in reactive arthritis.

1993

The local T-cell response to bacterial antigens is involved in the pathogenesis of reactive arthritis (ReA). Here, we have identified a 19-kDa antigen of Yersinia enterocolitica O:9 recognized by Yersinia-specific synovial fluid CD4+ T cells in two patients with Yersinia-induced ReA. N-terminal amino acid sequencing of this protein revealed that it was identical to the 19-kDa urease beta subunit of Y. enterocolitica O:9. This protein has previously been shown to be arthritogenic in preimmunized rats after intra-articular injection. Analysis of the T-cell response to this protein showed that it contains several T-cell epitopes, one of which cross-reacts with other enterobacteria not able to …

musculoskeletal diseasesProtein subunitT-LymphocytesImmunologyMolecular Sequence DataBiologyLymphocyte ActivationMicrobiologyEpitopeMicrobiologyAntigenProhibitinsSynovial FluidSynovial fluidHumansAmino Acid SequenceYersinia enterocoliticaHLA-DR AntigenYersinia enterocoliticaAntigens BacterialSequence Homology Amino AcidArthritisT lymphocyteHLA-DR Antigensbiology.organism_classificationbacterial infections and mycosesUreaseInfectious DiseasesParasitologyBacterial antigenResearch Article
researchProduct

297: Establishment of a chimeric NOD-scid/IL2RγcNull transplantation-model to evaluate graft-vs-host and graft-vs-leukemia immune responses of ex viv…

2007

musculoskeletal diseasesTransplantationbusiness.industryHost (biology)NodT lymphocyteHematologymedicine.diseaseVirologyTransplantationstomatognathic diseasesLeukemiaImmune systemimmune system diseaseshemic and lymphatic diseasesImmunologyMedicinebusinessEx vivoBiology of Blood and Marrow Transplantation
researchProduct

pentoxifylline inhibits vgamma9/vdelta2 t lymphocyte activation of patients with active behçet's disease

2007

The aim ofthis study is to evaluate the in vitro effect ofpentoxifylline (PTX) on T Vy9No21ymphocyte function in Beheet's disease (DO). We investigated the effect of PTX on Vy9No2 T cell expansion and expression of TNFRII receptor and perforin content before and after PTX addition by means of FACS analysis lymphocyte cultures from patients with active and inactive DO and healthy subjects. The addition of PTX at a concentration of 1 mg/ml determined a significant inhibition of cell expansion, a down regulation of TNF receptor expression and inhibited the PMA-induced degranulation of perforin. Taken together these data indicate that PTX is capable of interfering with Vy9No2 T cell function in…

pentoxifyllineBehcet s diseaseVy9/Vc>2 T lymphocyteBehcet s disease Vy9/Vc>2 T lymphocytes perforin pentoxifyllineperforin
researchProduct

Analysis of infiltrating γδ T cells in cutaneous melanoma: a hypothetic crosstalk for new immunotherapy

2022

Introduction: Melanoma is one of the most frequently occurring skin cancer and remains an important cause of mortality mainly in Caucasian populations. In clinical practice, the standard treatment for localized melanoma is surgical resection but for metastatic melanoma, few treatments are available, where chemo and radio-therapies are rarely indicated. Immunotherapy has revolutionized the management of metastatic melanoma that, as in others tumors, uses your body's own immune system to help fight cancer. Therapies targeting the immune checkpoint molecules have achieved objective responses in melanoma. Several receptors and/or ligands, such as PDL1, PD-1 and CTLA-4, have been identified as i…

γδ T lymphocytes.melanomaimmunotherapyimmunocheckpoint molecule
researchProduct